Unknown

Dataset Information

0

Wounding promotes ovarian cancer progression and decreases efficacy of cisplatin in a syngeneic mouse model.


ABSTRACT: Primary cytoreductive surgery followed by adjuvant chemotherapy is the standard treatment for advanced epithelial ovarian cancer. The average interval between surgery and chemotherapy initiation is approximately 4-weeks at most centers; however, since surgery may accelerate residual tumor growth, a shorter interval may be more beneficial.The murine ID8 cell model of ovarian cancer was used to examine the efficacy of cisplatin treatment administered perioperatively or 7 days after surgical wounding. Luciferase-expressing cells ID8 cells were injected intraperitoneally (i.p.) into female C57/Bl6 mice. Fourteen days post-injection, animals received an abdominal incision or anesthesia alone and received i.p. cisplatin either on the surgical day or 7 days later, or received no chemotherapy. Additional animals received cisplatin 28 days after wounding for comparison.Abdominal tumor mass increased 2.5-fold in wounded vs. unwounded animals as determined by bioluminescent in vivo tumor imaging. Cisplatin administered on the day of wounding decreased tumor burden by 50%, as compared to 90% in unwounded animals. Cisplatin on day 7 or day 28 decreased tumor burden by 80 and 37% respectively.Surgical wounding increases ovarian tumor mass and decreases perioperative cisplatin efficacy in this animal model. Administration of cisplatin 1 week after surgery was more effective than cisplatin administered perioperatively or 4 weeks after surgery.

SUBMITTER: Lee Y 

PROVIDER: S-EPMC6032528 | BioStudies | 2018-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC5356737 | BioStudies
1000-01-01 | S-EPMC4104995 | BioStudies
2013-01-01 | S-EPMC3868659 | BioStudies
2013-01-01 | S-EPMC3622195 | BioStudies
2013-01-01 | S-EPMC3709838 | BioStudies
2016-01-01 | S-EPMC4970724 | BioStudies
1000-01-01 | S-EPMC5715106 | BioStudies
2018-01-01 | S-EPMC6294677 | BioStudies
1000-01-01 | S-EPMC5706854 | BioStudies
1000-01-01 | S-EPMC3846584 | BioStudies